Answers are grounded in this paper and cite their sources.
Evaluates effectiveness of adriamycin in childhood malignancies, suggesting potential benefits over daunorubicin.
Adriamycin, a new antitumour antibiotic of the anthracycline group with a structural formula very similar to daunorubicin, has proved to have potent tumour-growth-inhibiting properties, and to be particularly effective in childhood malignancies. Though adriamycin produces a higher percentage of side-effects than daunorubicin-namely, stomatitis and alopecia-a lower dosage may be used for therapy.
No takes yet. Share an insight, caveat, or question.
Bonadonna et al. (1969) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: